



Docket No.: 20342/1202529-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Richard Franklin

Application No.: 10/762,566

Confirmation No.: 3220

Filed: January 23, 2004

Art Unit: 1614

For: FORMULATION AND METHODS FOR THE
TREATMENT OF THROMBOCYTHEMIA

Examiner: A. R. Hughes

AMENDMENT AFTER FINAL ACTION UNDER 37 C.F.R. 1.116

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

INTRODUCTORY COMMENTS

In response to the Office Action dated November 17, 2008, please consider the following remarks for the above-identified U.S. patent application.

The Listing of the Claims begins on page 3 of this paper.

Remarks/Arguments begin on page 8 of this paper.

This Response is accompanied by a Declaration of Gunnar Birgegård, M.D., Ph.D. under 37 C.F.R. §1.132, Exhibit 1 to the Declaration (Curriculum Vitae of Gunnar Birgegård, M.D., Ph.D.), Exhibit 2 to the Declaration (Souhami/Moxham, Textbook of Internal Medicine, Churchill-Livingstone, page 1043, table 25.53), Exhibit 3 to the Declaration (WHO Classifications 2008), Exhibit 4 to the Declaration (Italian and Nordic guidelines), an Information Disclosure Statement

listing Exhibits 2-4 to the Declaration and 1 additional reference, and a Request for Continued Examination (RCE) with the associated fee.

It is believed that no additional fee is required for this Amendment. However, should an additional fee be necessary in connection with the filing of this Response, or if a petition for extension of time is required for timely acceptance of the same, the Commissioner is hereby authorized and requested to charge Deposit Account No. 04-0100 for any such fees, and Applicant hereby petition for any needed extension of time.